Clinical Trial: NCT03029338
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Institute of Hematology & Blood Diseases Hospital, China |
| Information Provided By: | Institute of Hematology & Blood Diseases Hospital, China |
| Last Update Posted: | 2026-02-11 |
Study Overview
Brief Summary
In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.
Official Title
Conditions
Intervention / Treatment
- Biological: CD19 CAR T cells
Other Study ID Numbers
- QT2016003
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Institute of Hematology & Blood Diseases Hospital, China |
| Information Provided By: | Institute of Hematology & Blood Diseases Hospital, China |
| Last Update Posted: | 2026-02-11 |
Study Overview
Brief Summary
In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.
Official Title
Conditions
Intervention / Treatment
- Biological: CD19 CAR T cells
Other Study ID Numbers
- QT2016003